Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.150
-0.130 (-3.04%)
At close: Apr 28, 2026, 4:00 PM EDT
4.180
+0.030 (0.72%)
After-hours: Apr 28, 2026, 7:41 PM EDT

Arbutus Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-33.5-69.92-72.85-69.46-76.25
Upgrade
Depreciation & Amortization
0.361.381.41.431.75
Upgrade
Loss (Gain) From Sale of Assets
-0.67--0.02--
Upgrade
Asset Writedown & Restructuring Costs
2.810.17---
Upgrade
Loss (Gain) From Sale of Investments
-2.35-3.14-2.2-0.051
Upgrade
Stock-Based Compensation
6.958.999.37.186.42
Upgrade
Other Operating Activities
-3.220.5-3.34-3.7-1.39
Upgrade
Change in Accounts Receivable
1.38-0.63-0.42-0.450.41
Upgrade
Change in Accounts Payable
-2.11-2.71-5.765.221.91
Upgrade
Change in Unearned Revenue
-10.43-1.36-10.6622.46-
Upgrade
Change in Other Net Operating Assets
1.141.87-1.392.03-1.4
Upgrade
Operating Cash Flow
-39.64-64.85-85.94-35.36-67.53
Upgrade
Capital Expenditures
--0.18-1.01-0.51-0.81
Upgrade
Sale of Property, Plant & Equipment
0.36-0.02--
Upgrade
Investment in Securities
15.2223.1351.76-74.43-11.87
Upgrade
Investing Cash Flow
15.5822.9550.77-74.94-12.68
Upgrade
Issuance of Common Stock
5.725230.6531.81137.24
Upgrade
Financing Cash Flow
5.725230.6531.81137.24
Upgrade
Foreign Exchange Rate Adjustments
0.01-0.050.03-0.020.01
Upgrade
Net Cash Flow
-18.3210.05-4.49-78.5157.03
Upgrade
Free Cash Flow
-39.64-65.03-86.94-35.87-68.34
Upgrade
Free Cash Flow Margin
-281.45%-1053.83%-479.27%-91.92%-621.96%
Upgrade
Free Cash Flow Per Share
-0.21-0.35-0.52-0.24-0.64
Upgrade
Levered Free Cash Flow
-17.62-39.23-51.58-9.73-38.42
Upgrade
Unlevered Free Cash Flow
-17.56-39.15-51.3-8.65-36.63
Upgrade
Change in Working Capital
-10.02-2.83-18.2329.240.93
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.